Olezarsen Fast Tracked for Familial Chylomicronemia Syndrome
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Diagnosis & Disease Information
Vitamin D Supplementation Less Effective With Higher BMI
Further, baseline vitamin D-related biomarkers lower for individuals with higher BMI
Number of Daily Meals Linked to Weight Change in Adults
Increase of one daily meal associated with average difference in annual weight change of 0.28 kg
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
AAP Issues Guidelines for Children With Overweight, Obesity
Weight loss pharmacotherapy recommended as adjunct to health behavior and lifestyle treatment in children 12 years and older with obesity
MPR Weekly Dose Podcast #143
Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.
Wegovy Gains Approval for Treating Obesity in Adolescents
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Olpruva Approved for Patients With Urea Cycle Disorders
The application was approved through the FDA’s 505(b)(2) regulatory pathway.
Bitopertin Granted Orphan Drug Status for Erythropoietic Protoporphyria
Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 designed to modulate heme biosynthesis by limiting glycine uptake.
